-
1.发明公开GENETICALLY MODIFIED ECARIN AND PROCESS FOR PRODUCING THE SAME 有权遗传改良剂VERFAHREN ZU DESSEN HERSTELLUNG
公开(公告)号：EP1405912A1
公开(公告)日：2004-04-07
申请号：EP02745822.3
申请日：2002-07-04
IPC分类号： C12N15/12 , C07K14/435 , C12P21/02
CPC分类号： C12N9/6418
摘要： A recombinant ecarin protein that specifically activates prothrombin, said protein being efficiently prepared by the genetic engineering technique comprising the steps: (1) culturing a transformant microorganism or animal cell transformed with an expression vector in which a gene encoding ecarin is incorporated to the downstream of a promoter so as to produce and accumulate ecarin in culture supernatant or within said transformant and recovering the produced ecarin; and (2) purifying a solution containing the recovered ecarin to obtain purified ecarin. The present invention allows for production of recombinant ecarin on an industrial scale.
摘要翻译： 用于介导Arg-Ile位点上的凝血酶原-2切割以得到α-凝血酶或用于介导凝血酶原转化的中枢蛋白酶的遗传修饰的ecarin是新的。 还包括用于生产重组ecarin的独立权利要求，其包括：（a）培养通过转化微生物或动物细胞而构建的转化体，所述转化体携带携带启动子下游整合的ecarin的基因的表达载体，并收集所产生和累积的ecarin 在培养基或转化体中; 和（b）回收ecarin进行纯化。 活动：止血。 机制：内肽酶。
-
2.发明公开PEPTIDE FRAGMENTS HAVING CELL DEATH INHIBITORY ACTIVITY 有权PEPTIDFRAGMENTE MIT DEN ZELLTOD VERHINDERNDERAKTIVITÄT
公开(公告)号：EP1132402A1
公开(公告)日：2001-09-12
申请号：EP99972642.5
申请日：1999-11-12
CPC分类号： C07K14/4747 , A61K38/00
摘要： The present invention provides a peptide fragment or a series of peptide fragments having a cell death-inhibitory activity, having the amino acid sequence consisting of 103 amino acid residues at the C-terminal of selenoprotein P, or having said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or having a partial sequence of either of the above amino acid sequences, a medicament for treatment comprising said peptide fragment or a series of peptide fragments, an antibody to said peptide fragment or a series of peptide fragments, and a method for screening a cell death-inhibitory activity using said peptide fragment or a series of peptide fragments. The preferable peptide fragment or a series of peptide fragments of the present invention has the amino acid sequences shown in SEQ ID NO: 1 and/or SEQ ID NO: 2 or has a partial sequence thereof.
摘要翻译： 本发明提供具有细胞死亡抑制活性的肽片段或一系列肽片段，其具有由硒蛋白P的C末端上的103个氨基酸残基组成的氨基酸序列，或具有所述氨基酸序列与一个或多个 其中缺少，取代或添加的几个氨基酸残基或具有上述氨基酸序列之一的部分序列，包含所述肽片段或一系列肽片段的治疗药物，所述肽片段的抗体或一系列 的肽片段，以及使用所述肽片段或一系列肽片段筛选细胞死亡抑制活性的方法。 本发明优选的肽片段或一系列肽片段具有SEQ ID NO：1和/或SEQ ID NO：2所示的氨基酸序列或其部分序列。
-
3.发明公开NOVEL PREVENTIVES/REMEDIES FOR IMMUNOPATHY 审中-公开NEUE VORBEUGUNGSMEDIZIN / HEILMITTELFÜRIMMUNOPATHIEN
公开(公告)号：EP1055429A1
公开(公告)日：2000-11-29
申请号：EP99902905.1
申请日：1999-02-15
发明人： SASAKI, Takumi , KIMACHI, Kazuhiko , SOEJIMA, Kenji , KIMURA, Yumi , NOZAKI, Chikateru , FUJIYAMA, Yoshihide
CPC分类号： C07K14/31 , A61K38/164 , A61K39/085
摘要： A prophylactic/remedy for immunopathy for immunopathy comprising, as an active ingredient, modifications of Staphylococcal enterotoxin B (SEB) with substitution of at least one amino acid residues within the amino acid sequence of natural type SEB, or derivatives thereof, wherein said SEB modifications or derivatives thereof have inhibitory activity on T cell activation wherein they interact with specific Vβ component of T cell receptor (TCR) but are reduced in their immunological responsiveness to SEB without inducing elimination of T cells having specific Vβ component, the elimination being normally induced by natural type SEB or recombinant wild-type SEB.
摘要翻译： 作为免疫疾病免疫病的预防/治疗方法，其包含用天然型SEB的氨基酸序列中的至少一个氨基酸残基取代的葡萄球菌肠毒素B（SEB）或其衍生物作为活性成分的修饰，其中所述SEB修饰 或其衍生物对T细胞活化具有抑制活性，其中它们与T细胞受体（TCR）的特异性Vβ组分相互作用，但其对SEB的免疫应答降低，而不诱导具有特异性Vβ组分的T细胞的消除，消除正常 由天然型SEB或重组野生型SEB诱导。
-
4.发明授权ANTIBODY AGAINST ENZYME SPECIFICALLY CLEAVING VON VILLEBRAND FACTOR AND ASSAY SYSTEM USING THE SAME 有权单克隆抗体抗血管性血友病因子特异性切割酶和测定系统及其使用
公开(公告)号：EP1544293B1
公开(公告)日：2010-03-10
申请号：EP03798512.4
申请日：2003-09-25
发明人： SOEJIMA, Kenji , MIMURA, Noriko , MAEDA, Hiroaki , NOZAKI, Chikateru , HAMAMOTO, Takayoshi , NAKAGAKI, Tomohiro; c/o Kikuchi Research Center,
IPC分类号： C12N15/02 , C12N9/64 , C12N5/10 , C07K16/40 , C12P21/08 , A61K38/43 , A61K39/395 , A61P7/02 , G01N33/532 , G01N33/573 , G01N33/577
CPC分类号： C12N9/6489 , C07K16/40
-
公开(公告)号：EP2149584A1
公开(公告)日：2010-02-03
申请号：EP08751882.5
申请日：2008-04-18
CPC分类号： A61K39/0007 , A61K31/711 , C07K14/4711
摘要： An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine.
摘要翻译： 本发明的一个目的是提供用于增强免疫应答的安全有效的方法和用于预防或治疗阿尔茨海默病的药物，其包含诱导增强的免疫应答的β淀粉样肽。 使用该肽的增加或插入半胱氨酸的淀粉状蛋白β肽或其部分以及增强免疫应答的方法或使用该肽与佐剂一起增强免疫应答的方法。 一种预防或治疗阿尔茨海默病的药物，其包含诱导增强的免疫应答的淀粉状蛋白β肽或其部分。 可具有相同作用的DNA疫苗包含编码淀粉样蛋白β肽或其部分的基因，其通过添加或插入半胱氨酸诱导增强的免疫应答。
-
6.发明公开HUMAN POLYCLONAL ANTIBODY COMPOSITIONS 审中-公开ZUSAMMENSETZUNGEN MIT DEM HUMANEN POLYKLONALENANTIKÖRPER
公开(公告)号：EP1393746A1
公开(公告)日：2004-03-03
申请号：EP02717170.1
申请日：2002-04-16
申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute , KIRIN BEER KABUSHIKI KAISHA
IPC分类号： A61K39/395 , A61P31/04 , A61P31/12 , C07K16/12 , C07K16/08
CPC分类号： C07K16/1214 , A01K2217/05 , A61K2039/505 , C07K16/06 , C07K16/088 , C07K16/1081 , C07K16/1232 , C07K16/1271 , C07K16/1275 , Y02A50/39
摘要： A human polyclonal antibody having an antibacterial and/or antiviral activity with a desired titer and a wide spectrum; and human polyclonal antibody composition for preventing and treating infections which contain this antibody. The human polyclonal antibody composition for preventing or treating infections contain the human polyclonal antibody which is obtained by administering as immunogen a bacterium and/or a virus or a component of the bacterium and/or the virus to a non-human animal having a human antibody gene locus and has an antibody titer against the bacterium and/or the virus exceeding that of human pool plasma.
摘要翻译： 具有所需效价和广谱的抗细菌和/或抗病毒活性的人多克隆抗体; 和用于预防和治疗含有该抗体的感染的人多克隆抗体组合物。 用于预防或治疗感染的人多克隆抗体组合物含有人多克隆抗体，其通过作为免疫原将细菌和/或病毒或细菌和/或病毒的成分施用于具有人抗体的非人动物获得 并且对细菌和/或病毒的抗体滴度超过人池血浆的抗体滴度。
-
-
公开(公告)号：EP1437410A1
公开(公告)日：2004-07-14
申请号：EP02767954.7
申请日：2002-09-12
发明人： KAMINAKA, Sara , KAMINAKA, Kazuyoshi , HIRASHIMA, Masaki , MAEDA, Hiroaki , NOZAKI, Chikateru , TAKAHASHI, Kazuhiko
CPC分类号： C12N9/0065 , C07K14/765 , C07K2319/00
摘要： A novel selenocysteine-containing protein is provided which is a substantial entity having an enzymatic activity, typically an activity to reduce peroxide phospholipids. There are provided a gene consisting of a coding sequence for a protein not containing selenocysteine in which the codon for selenocysteine is introduced at a desired position and a selenocysteine insertion sequence resided at the 3'-end of said coding sequence and a protein expressed therefrom, typically a selenocysteine-containing protein having an activity to reduce peroxide phospholipids which is prepared by introducing selenocysteine into albumin and as well as a gene encoding said protein. A novel anti-oxidative substance is provided which can be applied for prevention of worsening, prophylaxis or treatment of various diseases associated with oxidative stress.
摘要翻译： 含有通过将一个或多个硒代半胱氨酸插入或取代含有硒代半胱氨酸的蛋白质并具有酶活性的骨架形成的重组硒蛋白的蛋白质是新的。 还包括以下独立权利要求：（1）编码这种重组的含半胱氨酸的蛋白质的基因; 和（2）通过使用该基因产生重组的含半胱氨酸的蛋白质。 活性：免疫调节剂; 抑制细胞生长; Cardiant; 精神药物; 神经保护; 降血糖; 眼科。 行动机制：源材料无。
-
9.发明公开
公开(公告)号：EP1374887A1
公开(公告)日：2004-01-02
申请号：EP01961246.4
申请日：2001-08-31
CPC分类号： A61K38/1709
摘要： A novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from said protein is provided. The novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, according to the present invention is suitably applicable to diseases with decrease in motor function.
摘要翻译： 提供了用于治疗神经变性疾病，特别是用于改善运动障碍的新型药物，其包含作为活性成分的硒蛋白P和/或肽片段或一系列源自所述蛋白质的肽片段。 根据本发明的用于治疗神经变性疾病，特别是用于改善运动障碍的新型药物适用于运动功能降低的疾病。
-
10.发明公开COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES 失效组成和丙型肝炎的方法对病毒病的复合材料的处理。
公开(公告)号：EP0662157A1
公开(公告)日：1995-07-12
申请号：EP93919644.0
申请日：1993-09-10
申请人： MOCHIDA PHARMACEUTICAL CO., LTD. , JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE , ISIS PHARMACEUTICALS, INC.
发明人： ANDERSON, Kevin, P. , HANECAK, Ronnie, C. , HOSHIKO, Kazuya , NOZAKI, Chikateru , NISHIHARA, Tsukasa , NAKATAKE, Hiroshi , HAMADA, Fukusaburo , ETO, Tatsuo , FURUKAWA, Shinichi
CPC分类号： C12N15/1131 , C07H21/00 , C07K14/005 , C12N2310/315 , C12N2310/33 , C12N2310/3521 , C12N2310/3527 , C12N2770/24222 , C12Q1/707
摘要： Antisense oligonucleotides are provided which are complementary to at least a portion of HCV RNA and specifically hybridizable therewith. These oligonucleotides can be administered to inhibit the replication of Hepatitis C virus in vivo or in vitro and to treat Hepatitis C virus-associated disease. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.018 秒)
